
An expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.

Your AI-Trained Oncology Knowledge Connection!


An expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.

An expert from Natera describes where future research needs to be focused for circulating tumor DNA testing in patients with colorectal cancer following the CIRCULATE-Japan study.

An expert from Natera shares multidisciplinary takeaways from the GALAXY cohort of the CIRCULATE-Japan study, assessing circulating tumor DNA as a prognostic biomarker for resectable colorectal cancer.

In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.

Published: November 6th 2018 | Updated: